Handelsbanken Fonder AB Grows Holdings in Ascendis Pharma A/S $ASND

Handelsbanken Fonder AB boosted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,267 shares of the biotechnology company’s stock after purchasing an additional 700 shares during the period. Handelsbanken Fonder AB’s holdings in Ascendis Pharma A/S were worth $2,117,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Allianz Asset Management GmbH grew its holdings in shares of Ascendis Pharma A/S by 144.7% during the second quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock worth $1,605,000 after buying an additional 5,500 shares during the last quarter. Vident Advisory LLC purchased a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $273,000. Goldman Sachs Group Inc. lifted its position in Ascendis Pharma A/S by 10.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock worth $91,269,000 after acquiring an additional 55,164 shares during the period. Hantz Financial Services Inc. grew its stake in shares of Ascendis Pharma A/S by 291.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Ascendis Pharma A/S in the second quarter valued at approximately $682,000.

Ascendis Pharma A/S Trading Down 1.1%

Shares of ASND opened at $206.65 on Wednesday. Ascendis Pharma A/S has a twelve month low of $118.03 and a twelve month high of $223.18. The firm has a market capitalization of $12.75 billion, a P/E ratio of -40.05 and a beta of 0.44. The firm’s 50-day moving average is $203.66 and its two-hundred day moving average is $187.18.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $290.24 million during the quarter, compared to analyst estimates of $246.91 million. Analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $295.00 target price (up previously from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Wolfe Research began coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 price target on the stock. UBS Group reissued a “buy” rating and set a $307.00 price target (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Bank of America lifted their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and a consensus target price of $256.60.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.